232 related articles for article (PubMed ID: 1719369)
1. Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations.
Zheng W; Rampe D; Triggle DJ
Mol Pharmacol; 1991 Nov; 40(5):734-41. PubMed ID: 1719369
[TBL] [Abstract][Full Text] [Related]
2. Functional interactions between two Ca2+ channel activators, (S)-Bay K 8644 and FPL 64176, in smooth muscle.
Rampe D; Dage RC
Mol Pharmacol; 1992 Apr; 41(4):599-602. PubMed ID: 1373795
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic and radioligand binding studies of 1,4-dihydropyridines in rat cardiac and vascular preparations: stereoselectivity and voltage dependence of antagonist and activator interactions.
Zheng W; Stoltefuss J; Goldmann S; Triggle DJ
Mol Pharmacol; 1992 Mar; 41(3):535-41. PubMed ID: 1372088
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the effects of a new Ca2+ channel activator, FPL 64176, in GH3 cells.
Kunze DL; Rampe D
Mol Pharmacol; 1992 Oct; 42(4):666-70. PubMed ID: 1279375
[TBL] [Abstract][Full Text] [Related]
5. Voltage-dependent binding of 1,4-dihydropyridine Ca2+ channel antagonists and activators in cultured neonatal rat ventricular myocytes.
Wei XY; Rutledge A; Triggle DJ
Mol Pharmacol; 1989 Apr; 35(4):541-52. PubMed ID: 2539561
[TBL] [Abstract][Full Text] [Related]
6. A new site for the activation of cardiac calcium channels defined by the nondihydropyridine FPL 64176.
Rampe D; Lacerda AE
J Pharmacol Exp Ther; 1991 Dec; 259(3):982-7. PubMed ID: 1662279
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the in vitro and in vivo cardiovascular effects of two structurally distinct Ca++ channel activators, BAY K 8644 and FPL 64176.
Rampe D; Anderson B; Rapien-Pryor V; Li T; Dage RC
J Pharmacol Exp Ther; 1993 Jun; 265(3):1125-30. PubMed ID: 7685384
[TBL] [Abstract][Full Text] [Related]
8. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
Zahradníková A; Minarovic I; Zahradník I
J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle.
Wei XY; Luchowski EM; Rutledge A; Su CM; Triggle DJ
J Pharmacol Exp Ther; 1986 Oct; 239(1):144-53. PubMed ID: 2428971
[TBL] [Abstract][Full Text] [Related]
10. Allosteric interactions at L-type calcium channels between FPL 64176 and the enantiomers of the dihydropyridine Bay K 8644.
Usowicz MM; Gigg M; Jones LM; Cheung CW; Hartley SA
J Pharmacol Exp Ther; 1995 Nov; 275(2):638-45. PubMed ID: 7473149
[TBL] [Abstract][Full Text] [Related]
11. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
[TBL] [Abstract][Full Text] [Related]
12. Ca2+ channel modulation alters halothane-induced depression of ventricular myocytes.
Kanaya N; Matsumoto M; Kawana S; Tsuchida H; Kimura H; Miyamoto A; Ohshika H; Namiki A
Can J Anaesth; 1998 Jun; 45(6):584-91. PubMed ID: 9669017
[TBL] [Abstract][Full Text] [Related]
13. SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies.
Polster P; Christophe B; Van Damme M; Houlliche A; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):593-9. PubMed ID: 1700816
[TBL] [Abstract][Full Text] [Related]
14. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes.
Hamilton SL; Yatani A; Brush K; Schwartz A; Brown AM
Mol Pharmacol; 1987 Mar; 31(3):221-31. PubMed ID: 2436031
[TBL] [Abstract][Full Text] [Related]
15. A novel high affinity class of Ca2+ channel blockers.
Qar J; Barhanin J; Romey G; Henning R; Lerch U; Oekonomopulos R; Urbach H; Lazdunski M
Mol Pharmacol; 1988 Apr; 33(4):363-9. PubMed ID: 2965787
[TBL] [Abstract][Full Text] [Related]
16. Influence of Mg++ on the effect of diltiazem to increase dihydropyridine binding to receptors on Ca++-channels in chick cardiac and skeletal muscle membranes.
Maan AC; Ptasienski J; Hosey MM
J Pharmacol Exp Ther; 1986 Dec; 239(3):768-74. PubMed ID: 2432217
[TBL] [Abstract][Full Text] [Related]
17. Effect of the Ca(2+)-channel agonist Bay K 8644 on the contractile responses in human placental veins.
Barrús MT; Reviriego J; Marín J
J Auton Pharmacol; 1996 Jun; 16(3):161-7. PubMed ID: 8884463
[TBL] [Abstract][Full Text] [Related]
18. Calcium channel agonist and antagonist binding in a highly enriched sarcolemma preparation obtained from canine ventricle.
Rampe D; Poder T; Zhao ZY; Schilling WP
J Cardiovasc Pharmacol; 1989 Apr; 13(4):547-56. PubMed ID: 2470991
[TBL] [Abstract][Full Text] [Related]
19. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
Hargreaves AC; Gunthorpe MJ; Taylor CW; Lummis SC
Mol Pharmacol; 1996 Nov; 50(5):1284-94. PubMed ID: 8913360
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of the binding of [3H]nitrendipine to rabbit ventricular membranes: modification by other Ca++ channel antagonists and by the Ca++ channel agonist Bay K 8644.
Janis RA; Sarmiento JG; Maurer SC; Bolger GT; Triggle DJ
J Pharmacol Exp Ther; 1984 Oct; 231(1):8-15. PubMed ID: 6208356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
